Analysis reveals that the identifier "LS-009" does not correspond to a singular, recognized pharmaceutical drug or medication. The query for an "LS-009 medication" is based on a foundational misconception. Instead, "LS-009" is a polysemous identifier, meaning it is a code or name used for numerous, entirely unrelated entities across a wide spectrum of industries and disciplines. This report provides a definitive deconstruction of these various meanings, correcting the initial premise and categorizing each distinct use of the "LS-009" identifier to enable accurate, context-specific understanding.
The recurrence of "LS-009" across disparate fields is not coincidental but is a direct consequence of decentralized and uncoordinated internal nomenclature systems. Organizations in fields as diverse as materials science, clinical research, automotive manufacturing, and consumer goods independently generate internal part numbers, formulation codes, and tracking IDs. Without a global registry or standardizing body for such internal codes, the same alphanumeric string can and does get assigned to multiple different items. This phenomenon of "identifier collision" is the primary source of the confusion surrounding "LS-009." Any investigation based on such a non-universal identifier must therefore be acutely aware of context and cannot rely on a simple string search for accurate due diligence.
The "LS-009" identifier has been located in several distinct domains, each with a unique context and meaning. This report will provide a detailed examination of the identifier as it appears in the following categories:
It is concluded that any further investigation premised on the existence of a single "LS-009 medication" should be abandoned. Such an approach is guaranteed to yield misleading or invalid results. Instead, strategic focus must be redirected toward one of the specific, correctly identified entities detailed within this report, depending on the user's area of interest.
The initial confusion regarding "LS-009" is significantly amplified by the existence of several identifiers in fields that are adjacent to or associated with pharmaceuticals. A search for a medication that returns results including "clinical trial," "pharmacology," and "medicine shelf" creates a misleading "cluster of plausibility," suggesting the user is on a correct path. This section systematically dissects this cluster, demonstrating that while these identifiers exist within a broadly medical domain, none represent a regulated therapeutic drug. Each is a distinct entity with a specific, non-therapeutic function.
The most prominent medical-related use of "LS-009" is as an administrative tracking code for research activities, not as an identifier for a substance being tested.
The code "2016-LS-009" is an ethical approval number assigned to a specific site participating in a multicenter clinical study.[1] The study was designed to evaluate the clinical performance of the Xpert CT/NG test, a diagnostic assay for the detection of
Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG).[3] The approval number "2016-LS-009" specifically pertains to the activities conducted at the Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, one of three hospitals involved in the evaluation.[1]
The significance of this finding is critical. The code identifies a study protocol, not a compound. The subject of the study was a diagnostic device, and its purpose was to validate the test's sensitivity and specificity using urine and cervical swab samples.[1] This type of identifier is issued by an institutional review board (IRB) or ethics committee to certify that a research plan meets ethical standards and is permitted to proceed. It must not be confused with a marketing authorization number from a regulatory body like the U.S. Food and Drug Administration (FDA), which permits a new drug to be sold to the public. The "approval" in this context is for the research itself, not for a therapeutic product.
The identifier "LS 009" also appears as a collection tag for a biological sample in the context of natural product discovery.
In an ethnobotanical survey conducted in Uganda, "LS 009" was the unique identifier assigned to a plant specimen known locally as "Omululuza".[4] The study documented the traditional uses of various plants, noting that a decoction made from the leaves (L) and stems (S) of this specimen is used to treat conditions including malaria, diarrhea, stomach ache, and COVID-19.[5] This research, which was approved by university ethics committees and the Uganda National Council of Science and Technology, represents the earliest stage of pharmacological investigation—the identification of natural products that may serve as sources for "new drugs and drug leads".[4] "LS 009" is therefore the tag for a raw, unpurified botanical material, not a standardized, clinically-validated pharmaceutical.
The "LS-009" code is also used to identify tools and reference materials used in fundamental laboratory work.
In the field of genetic engineering, "LS-009" was the name given to a specific primer used in a laboratory experiment.[6] A primer is a short, custom-synthesized strand of nucleic acid that serves as a starting point for DNA synthesis. In this case, the "LS-009" primer was used in a polymerase chain reaction (PCR) to amplify a specific gene (
yoeBsl) from the bacterium Streptomyces lividans.[6] This establishes "LS-009" as a common laboratory consumable, a tool whose identity is defined by its specific genetic sequence and whose purpose is purely technical. It has no therapeutic application.
The World Health Organization (WHO) BioHub System uses a similar coding convention for tracking biological materials. The identifier "2021-WHO-LS-009" is the official reference code for a specific virus sample: the SARS-CoV-2 Gamma variant (lineage P.1), strain hCoV-19/ LU-LNS/2021.[7] This system is designed to facilitate the safe and rapid sharing of pathogens between laboratories for research and public health purposes. Here, "LS-009" is part of an administrative code for a dangerous pathogen, further reinforcing the theme of the identifier being used for tracking and reference rather than for a therapeutic substance.
Beyond its use as an administrative identifier, "LS-009" also refers to two distinct chemical products. These products exist in entirely separate markets and serve vastly different purposes. The first is a high-purity research chemical intended for industrial R&D in the energy sector. The second is a code for a complex formulation intended for the mass-market consumer cosmetics industry. The identity of "LS-009" as a chemical is therefore bifurcated, and understanding this division is essential for any accurate market or technical intelligence.
One of the most technically specific uses of the "LS-009" identifier is for a specialized electrolyte used in advanced battery research.
The electrolyte is explicitly defined as a solution of "1.0 M LiTFSI in 1,3-dioxalane (DOL):dimethyl ether (DME) = 1:1 vol % with 2.0% LiNO3".[8] LiTFSI is lithium bis(trifluoromethanesulfonyl)imide, a common salt in lithium battery research. This formulation is offered by a chemical company named DoDoChem.[8] Another supplier, "col-int.com," lists "LS-009" for sale at a price of $1,320.00 for 1000g, a price point indicative of a low-volume, high-purity specialty chemical for research and development, not a mass-produced commodity.[9]
This "LS-009" electrolyte is a critical component in the development of next-generation energy storage systems, particularly lithium-sulfur (Li-S) and lithium metal batteries.[8] These battery types have a much higher theoretical energy density than conventional lithium-ion batteries but are plagued by practical challenges, most notably the formation of lithium dendrites during charging.[8] Dendrites are needle-like structures that can grow from the anode, causing short circuits, capacity loss, and safety hazards. The "LS-009" electrolyte is used in research aimed at creating a stable solid-electrolyte interphase (SEI) and enabling uniform, dendrite-free lithium deposition. Studies cite its use in conjunction with advanced anode architectures, such as 3D carbon nanofiber hosts and composite lithium soap fiber interfaces, to improve battery cycle life and efficiency.[8]
This version of "LS-009" is not a final product but an enabling material for a highly strategic and competitive R&D field. The research it supports is aimed at creating batteries for electric vehicles, large-scale grid storage, and advanced mobile electronics.[13] The market is a business-to-business (B2B) ecosystem comprising research universities, national laboratories, and the R&D departments of battery manufacturers and technology firms.
In a completely different context, "LS-009" is used as an internal formulation code for a consumer cosmetic product.
The code "SC-LS 009 V3" refers to an "Intensely Hydrating Lip Balm Treatment" developed by the specialty chemical company AppleChem.[14] This is unequivocally a cosmetic product, not a drug, designed for topical application to the lips for hydration and aesthetic improvement.
The key technological feature of this formulation is its water-in-oil emulsion base. This is presented as an innovation over standard wax-based lip balms, claiming to provide "dramatically more hydration".[14] The formulation leverages several key ingredients to achieve its properties: OleoFlex structurants are used to create a stable, water-resistant film with a "smooth and cushioned feel," while PhytoCare, a snow mushroom extract, is included to hydrate, repair skin, and help rebuild elasticity.[14]
The cosmetic nature of this product is confirmed by its list of ingredients, which are standard components in the personal care industry. The complete formulation provides definitive evidence of its identity.
Table 1: Formulation of SC-LS 009 V3 Intensely Hydrating Lip Balm Treatment
Phase | Ingredient Name (INCI Name) | Usage Weight % |
---|---|---|
A | Prunus Amygdalus Dulcis (Sweet Almond) Oil | 4.00 |
Shea Butter | 8.00 | |
Sunflower Seed Oil | 15.00 | |
Caprylic/Capric Triglyceride | 15.00 | |
OleoFlex FG 100 | 9.00 | |
OleoFlex EG 200 | 15.00 | |
Polyethylene | 6.00 | |
Ozokerite Wax 77W | 6.00 | |
Microcrystalline Wax | 5.50 | |
Carnauba Wax | 2.00 | |
Beeswax | 4.00 | |
B1 | Glycerine | 20.00 |
Snow Mushroom Extract (PhytoCare-HA CG 1M) | 0.10 | |
Honey | 4.00 | |
Sorbitan Laurate | 0.50 | |
Water | 47.40 | |
B2 | Caprylic/Capric Triglyceride | 16.00 |
2-Ethylhexyl Palmitate | 2.50 | |
PEG -30 Dipolyhydroxystearate | 2.00 | |
OleoFlex FG 100 | 5.00 | |
OleoFlex EG 200 | 2.50 | |
C | Preservative | 0.50 |
Note: Phase B is a premixed water-in-oil (W/O) emulsion that constitutes 10.0% of the final product. The percentages for Phases B1 and B2 represent the composition of that premixed emulsion. 14 |
To provide a complete picture of the "identifier collision" phenomenon, this section catalogues the remaining, disparate uses of the "LS-009" code. These examples, drawn from various industries, serve to definitively eliminate these items from any consideration as a medication and highlight the importance of contextual analysis.
The comprehensive analysis confirms that the query for an "LS-009 medication" is based on a false premise. This error arises from a widespread "identifier collision," where a single alphanumeric code has been independently assigned to numerous, unrelated entities across different fields. This report has systematically deconstructed this premise, separating the plausible but incorrect leads in the medical field from the genuine identities of "LS-009" in domains such as materials science, cosmetics, and industrial manufacturing. The evidence demonstrates that "LS-009" is, among other things, a clinical study approval number, a botanical specimen tag, a battery electrolyte, a cosmetic formulation, and an automotive part, but it is not a recognized pharmaceutical drug.
The following table serves as the capstone of this analysis, providing a single, actionable reference artifact that distills the report's findings. It offers a definitive guide to the true identities of "LS-009," empowering any user to pivot their research correctly by providing the necessary context, description, and source validation for each entity.
Table 2: Definitive Reference Guide to the "LS-009" Identifier
Identifier/Code | Domain/Industry | True Identity | Key Characteristics/Description | Source(s) |
---|---|---|---|---|
2016-LS-009 | Clinical Research | Ethical Approval Number | For a multicenter study evaluating the Xpert CT/NG diagnostic test in China. | 1 |
LS 009 | Ethnobotany | Plant Specimen Tag | A plant known as "Omululuza" from a Ugandan survey, used in traditional medicine. | 4 |
LS-009 | Materials Science | Battery Electrolyte | A solution of 1.0 M LiTFSI in DOL:DME with LiNO3, used in Li-S battery R&D. | 8 |
SC-LS 009 V3 | Cosmetics | Lip Balm Formulation | A water-in-oil emulsion base for an intensely hydrating lip treatment by AppleChem. | 14 |
LS-009 | Medical Equipment | Hospital Furniture | An epoxy-painted, two-sided stainless steel medicine shelf rack. | 15 |
CTS-LS-009 | Automotive | Lowering Springs | Aftermarket performance part for the Volkswagen MK8 GTI, made by CTS Turbo. | 16 |
LS-009 | Molecular Biology | Laboratory Primer | A custom DNA primer used to amplify the yoeBsl gene from S. lividans. | 6 |
2021-WHO-LS-009 | Global Public Health | Pathogen Strain Code | WHO BioHub identifier for SARS-CoV-2 Gamma variant (P.1) sample. | 7 |
LS-009 | Industrial Machinery | Mechanical Part | A 5×30 mm spring pin listed in a parts manual for a milling machine. | 19 |
LS-009 | Industrial Couplings | Product Model Number | A self-sealing coupling for fluid transfer systems, made by WALTHER. | 20 |
LS-009 | Consumer Goods | Product Color Code | The color code for "Dark Oak Log & Siding" transparent wood stain by PPG Proluxe. | 21 |
3M LS 009 | Quality Control | Internal Test Method | A 3M standard procedure for testing the surface appearance of protective films. | 22 |
It is strongly recommended that the search for "LS-009" as a singular pharmaceutical entity be definitively concluded. Continuing this line of inquiry carries a high risk of leading to misinformed strategic decisions based on flawed data. Any future research, investment, or due diligence must be precisely targeted toward one of the actual entities identified in this report. For example, a valid line of inquiry would be "the market for lithium-sulfur battery electrolytes," "the competitive landscape for water-in-oil cosmetic formulations," or "the supply chain for CTS Turbo automotive parts." By using the correct context and terminology as laid out in this analysis, future efforts can proceed from a foundation of factual accuracy.
Published at: July 7, 2025
This report is continuously updated as new research emerges.
Empowering clinical research with data-driven insights and AI-powered tools.
© 2025 MedPath, Inc. All rights reserved.